ANI Pharmaceuticals, Inc.
ANIP
$81.89
-$0.78-0.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 227.81M | 211.37M | 197.12M | 190.57M | 148.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.81M | 211.37M | 197.12M | 190.57M | 148.33M |
| Cost of Revenue | 93.39M | 74.62M | 73.04M | 83.50M | 63.08M |
| Gross Profit | 134.42M | 136.76M | 124.09M | 107.07M | 85.26M |
| SG&A Expenses | 76.26M | 81.57M | 75.63M | 69.52M | 69.28M |
| Depreciation & Amortization | 22.63M | 23.28M | 22.89M | 22.60M | 15.75M |
| Other Operating Expenses | -- | -- | -- | -- | 2.54M |
| Total Operating Expenses | 204.58M | 196.00M | 182.12M | 192.27M | 160.76M |
| Operating Income | 23.23M | 15.37M | 15.00M | -1.70M | -12.43M |
| Income Before Tax | 33.80M | 10.53M | 19.99M | -13.76M | -31.50M |
| Income Tax Expenses | 7.18M | 1.98M | 4.31M | -3.49M | -7.33M |
| Earnings from Continuing Operations | 26.62M | 8.55M | 15.68M | -10.28M | -24.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.62M | 8.55M | 15.68M | -10.28M | -24.17M |
| EBIT | 23.23M | 15.37M | 15.00M | -1.70M | -12.43M |
| EBITDA | 45.86M | 38.65M | 37.89M | 20.91M | 3.32M |
| EPS Basic | 1.19 | 0.37 | 0.70 | -0.55 | -1.27 |
| Normalized Basic EPS | 0.55 | 0.37 | 0.31 | -0.29 | -0.48 |
| EPS Diluted | 1.13 | 0.36 | 0.69 | -0.55 | -1.27 |
| Normalized Diluted EPS | 0.52 | 0.36 | 0.30 | -0.29 | -0.48 |
| Average Basic Shares Outstanding | 20.07M | 19.83M | 19.61M | 19.45M | 19.40M |
| Average Diluted Shares Outstanding | 21.09M | 20.31M | 20.05M | 19.45M | 19.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.29% | 4.76% | 2.59% | -3.95% | -1.68% |